Document Detail


Interaction of maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala polymorphism with fetal sex affects maternal glycemic control during pregnancy.
MedLine Citation:
PMID:  20032817     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It was suggested that fetal sex may substantially affect maternal glycemic control during pregnancy in genetically susceptible mothers. The peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is known to affect glycemic control and may act in a sex-specific manner. This polymorphism is thus an attractive candidate to test this hypothesis using a second independent functionally relevant polymorphism. We analyzed the impact of fetal sex on maternal glycemic control during pregnancy in relation to the maternal PPARgamma2 Pro12Ala polymorphism. Two-thousand fourteen Caucasian women without preexisting diabetes and preexisting hypertension with singleton pregnancies delivering consecutively at the Charit? obstetrics department were genotyped. Glycemic control was analyzed by measuring total glycated hemoglobin at birth. Correction for confounding factors and multiple testing was considered in the analysis. The maternal PPARgamma2 Pro12Ala polymorphism without consideration of fetal sex had no effect on blood pressure, new onset of proteinuria and total glycated hemoglobin at delivery. Mothers carrying both G alleles (GG genotype) delivering a girl had a higher (P = 0.015) total glycated hemoglobin (6.81 or - 0.50%) versus mothers carrying the same alleles but delivering boys (5.85 + or - 0.58%). Comparing mothers with the GG genotype delivering girls with mothers with CC or CG genotypes also delivering girls (6.32 + or - 0.72%) revealed a significantly higher maternal total glycated hemoglobin at delivery in the former group (P < 0.009). Fetal sex/sex chromosomes may substantially affect maternal glycemic control in mothers who are carriers of the GG alleles of the PPARgamma2 Pro12Ala polymorphism.
Authors:
Berthold Hocher; Ludwig Schlemm; Hannah Haumann; Christine Poralla; You-Peng Chen; Jian Li; Florian Guthmann; Christian Bamberg; Karim D Kalache; Thiemo Pfab
Related Documents :
22977837 - Study of proliferative processes and nuclear estradiol and progesterone receptors in my...
10693607 - Effects on the foetus of exercise in pregnancy.
2367647 - Pregnancy and maternity leave: aawr survey results.
19304947 - Hypoxia during pregnancy in rats leads to early morphological changes of atherosclerosi...
19370567 - Intra-uterine insemination versus fallopian tube sperm perfusion for non-tubal infertil...
23922817 - Sperm recovery and ivf after testicular sperm extraction (tese): effect of male diagnos...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacogenetics and genomics     Volume:  20     ISSN:  1744-6880     ISO Abbreviation:  Pharmacogenet. Genomics     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-03-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231005     Medline TA:  Pharmacogenet Genomics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  139-42     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Institute of Pharmacology, Charit?, Berlin, Germany. berthold.hocher@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine / genetics
Amino Acid Substitution / genetics*
Blood Glucose / genetics*
Female
Fetus / physiology*
Genetic Predisposition to Disease
Humans
Male
PPAR gamma / genetics*
Polymorphism, Single Nucleotide / genetics*
Pregnancy
Proline / genetics
Sex Characteristics*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/PPAR gamma; 147-85-3/Proline; 56-41-7/Alanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The GSTP1 Ile105 Val polymorphism modifies the metabolism of toluene di-isocyanate.
Next Document:  Development of a Pharmacogenetic Predictive Test in asthma: proof of concept.